Claims for Patent: 8,715,665

Summary for Patent: 8,715,665

Title:	Methods for treating cancer resistant to ErbB therapeutics
Abstract:	Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
Inventor(s):	Janne; Pasi A. (Newton, MA), Engelman; Jeffrey (Chestnut Hill, MA), Cantley; Lewis C. (Cambridge, MA)
Assignee:	The General Hospital Corporation (Boston, MA) Dana Farber Cancer Institute (Boston, MA) Beth Israel Deaconess Medical Center (Boston, MA)
Application Number:	12/450,826
Patent Claims:	1. A method for treating non-small cell lung cancer (NSCLC) or gastric cancer in a patient with an acquired resistance to treatment with an anti-ErbB therapeutic, comprising the steps of: a) selecting a patient with NSCLC or gastric cancer associated with an ErbB activating mutation or an ErbB gene amplification who has developed a resistance to treatment with an anti-ErbB therapeutic, and whose cancer cells comprise cells with a MET activating mutation or a MET gene amplification that reduces downregulation of PI3K/Akt signaling in response to the anti-ErbB therapeutic, and b) administering to said patient an anti-ErbB therapeutic and an anti-MET therapeutic. 2. The method of claim 1, wherein the subject has an EGFR, ErbB2, ErbB3, or ErbB4 activating mutation or gene amplification. 3. The method of claim 2, wherein the subject has an EGFR activating mutation or an EGFR gene amplification. 4. The method of claim 1, wherein the cancer is resistant to treatment with one or more of the following anti-ErbB therapeutics: an anti-EGFR therapeutic, an anti-ErbB2 therapeutic, an anti-ErbB3 therapeutic, or an anti-ErbB4 therapeutic. 5. The method of claim 1, wherein the cancer is resistant to treatment with one or more of the following anti-ErbB therapeutics: a small molecule therapeutic, a nucleic acid therapeutic, or a protein therapeutic. 6. The method of claim 5, wherein the cancer is resistant to treatment with an anti-ErbB antibody. 7. The method of claim 5, wherein the cancer is resistant to treatment with an ErbB kinase inhibitor. 8. The method of claim 5, wherein the cancer is resistant to treatment with an EGFR kinase inhibitor. 9. The method of claim 1, wherein the anti-ErbB therapeutic is selected from the group consisting of gefitinib, erlotinib, lapatinib, PF00299804, CI-1033, EKB-569, BIBW2992, ZD6474, AV-412, EXEL-7647, HKI-272, cetuximab, pantinumumab, and trastuzumab. 10. The method of claim 1, wherein the anti-MET therapeutic is selected from the group consisting of PHA-665,752, SU11274, SU5416, PF-02341066, XL-880, MGCD265, XL184, ARQ 197, P-470, SGX-523, JNJ38877605, AMG 102, and OA-5D5. 11. The method of claim 1, wherein: a) the anti-ErbB therapeutic is selected from the group consisting of gefitinib, erlotinib, lapatinib, PF00299804, CI-1033, EKB-569, BIBW2992, ZD6474, AV-412, EXEL-7647, HKI-272, cetuximab, pantinumumab, and trastuzumab; and b) the anti-MET therapeutic is selected from the group consisting of PHA-665,752, SU11274, SU5416, PF-02341066, XL-880, MGCD265, XL184, ARQ 197, P-470, SGX-523, JNJ38877605, AMG 102, and OA-5D5. 12. The method of claim 1, wherein the anti-ErbB therapeutic is gefitinib and the anti-MET therapeutic is PHA-665,752.

Details for Patent 8,715,665

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-04-13
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-04-13
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2027-04-13
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2027-04-13